New hope for tough esophageal cancers: adding low-dose radiation to immunotherapy
NCT ID NCT07272291
First seen Jan 04, 2026 · Last updated Jun 16, 2026 · Updated 26 times
Summary
This study is for people with esophageal cancer that did not shrink after standard pre-surgery treatment. It tests whether adding low-dose radiation to a drug called toripalimab (an immunotherapy) plus chemotherapy can help more tumors shrink before surgery. About 48 adults will receive the combination, then have surgery. After surgery, some may continue toripalimab for up to a year to keep the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.